Tag:

Cambria Biosciences

Latest Headlines

ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc

November 12, 2007

> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis.

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

MORE EVENTS

Press Releases

Featured Jobs

Entry Level Process Engineer and Lead Process Engineer
Foster Wheeler Biokinetics - San Francisco, CA
Sr. IT Infrastructure Architect Job
Celgene Corporation - Berkeley Heights, NJ, US
Director, Clinical Safety
Daiichi Sankyo - Edison, NJ
Statistician Job
Yoh - Montville, NJ, USA
Quality Assurance Specialist Job
Yoh - Lexington, MA, USA

Cambria Biosciences

Latest Headlines

Latest Headlines

ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

Cambria Biosciences

Latest Headlines

Latest Headlines

ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc

Related Tags